Hims & Hers Health Inc (NYSE:HIMS) shares traded 4.43% higher at $38.93 on Wall Street last session.
HIMS stock price is now 33.48% away from the 50-day moving average and 84.30% away from the 200-day moving average. The market capitalization of the company currently stands at $8.51B.
With the price target enhanced from $24 to $25, Citigroup Downgraded its rating from Neutral to Sell for Hims & Hers Health Inc (NYSE: HIMS). On January 07, 2025, BTIG Research recently initiated its ‘Buy’ rating on the stock quoting a target price of $35, while ‘Morgan Stanley’ rates the stock as ‘Overweight’
In other news, Boughton Soleil, Officer bought 4,153 shares of the company’s stock on Feb 03 ’25. The stock was bought for $146,601 at an average price of $35.30. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 03 ’25, Officer Chi Michael bought 2,054 shares of the business’s stock. A total of $72,506 was incurred on buying the stock at an average price of $35.30. A total of 18.75% of the company’s stock is owned by insiders.
During the past 12 months, Hims & Hers Health Inc has had a low of $8.51 and a high of $37.96. As of last week, the company has a debt-to-equity ratio of 0.03, a current ratio of 2.14, and a quick ratio of 1.82. The fifty day moving average price for HIMS is $28.8072 and a two-hundred day moving average price translates $20.9915 for the stock.
The latest earnings results from Hims & Hers Health Inc (NYSE: HIMS) was released for 2024-09-30. The net profit margin was 8.15% and return on equity was 26.35% for HIMS. The company reported revenue of $401.56 million for the quarter, compared to $226.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 77.13 percent. For the current quarter, analysts expect HIMS to generate $469.68M in revenue.
